School of Public Health, Fudan University, Shanghai, China.
Department of General Affairs and Emergency Response, Changing District Centers for Disease Control and Prevention, Shanghai, China.
Expert Rev Vaccines. 2019 Nov;18(11):1187-1199. doi: 10.1080/14760584.2019.1688150. Epub 2019 Nov 13.
: China has made remarkable achievements in the field of immunization. However, several widespread vaccine safety-related events have recently received worldwide attention and reflect flaws in vaccine management. This study aimed to summarize vaccine safety-related events between 1985 and 2018 in China and analyze the profit motives of these events.. Literature and media reviews were conducted to discover vaccine safety-related events. We developed a conceptual model with profit-related variables, and using information available from each event, we identified which profit-related variable was implicated, and how it related to the pursuit of higher profits.: A total of 39 vaccine safety-related events were found in vaccine production, procurement, transportation, and daily management, along with adverse events following immunization (AEFIs). Overall, 90% (35/39) of the events could be classified as profit-driven. The motives of most events could be tied to one or more reasons, including decreasing costs among vaccine producers (67%, 26/39), reducing actual procurement price (67%, 26/39), and reducing costs of transportation and/or cold chain (24/39, 62%).: In order to deal with vaccine-related challenges, a more restrictive supervision system on vaccine production and more emergency preparedness, including health and risk communication strategies, for vaccine safety should be implemented.
中国在免疫领域取得了显著成就。然而，最近一些广泛关注的疫苗安全相关事件引起了全球关注，反映出疫苗管理存在缺陷。本研究旨在总结 1985 年至 2018 年期间中国发生的疫苗安全相关事件，并分析这些事件的盈利动机。通过文献和媒体回顾发现了疫苗安全相关事件。我们制定了一个包含盈利相关变量的概念模型，并利用每个事件的可用信息，确定了哪些盈利相关变量受到影响，以及它们与追求更高利润的关系。在疫苗生产、采购、运输和日常管理以及预防接种后不良反应（AEFIs）方面，共发现 39 起疫苗安全相关事件。总体而言，90%（35/39）的事件可归类为盈利驱动。大多数事件的动机可以归结为一个或多个原因，包括疫苗生产商降低成本（67%，26/39）、降低实际采购价格（67%，26/39）和降低运输和/或冷链成本（24%，26/39，62%）。为了应对疫苗相关挑战，应实施更严格的疫苗生产监管制度，并为疫苗安全做好更充分的应急准备，包括卫生和风险沟通策略。
